Date published: 2025-10-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

Jaw1 Inhibitors

Jaw1 inhibitors encompass a specialized category of chemical agents designed to modulate the function of the Jaw1 protein, also known as lymphoid-restricted membrane protein (LRMP). Jaw1 is implicated in intracellular processes related to the endoplasmic reticulum, where it is thought to play a role in the regulation of protein secretion and membrane dynamics. Inhibitors targeting Jaw1 are tailored to interact with the protein in a way that alters its normal activity, typically through binding to its active sites or regions essential for its structural integrity. The interaction between Jaw1 and its inhibitors is complex, often involving the disruption of the protein's ability to engage in its normal cellular functions. The development of Jaw1 inhibitors is a sophisticated process that starts with an extensive understanding of the protein's structure and the identification of potential binding sites for small molecules. This process leverages advanced computational modeling, biophysical characterization, and high-resolution structural determination techniques like X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy to map out the interaction landscape of Jaw1 and to design molecules that can effectively target these sites.

Chemists and molecular biologists work collaboratively to synthesize and optimize Jaw1 inhibitors, iterating through cycles of design and testing to refine the molecular structures for enhanced specificity and binding affinity. The molecular architecture of these inhibitors often includes a variety of chemical motifs and functional groups that are strategically incorporated to exploit the unique features of Jaw1's binding pockets. The inhibitors' design is further guided by structure-activity relationship (SAR) studies, which examine the effect of structural changes on the interaction with Jaw1. This iterative process helps in fine-tuning the inhibitors to achieve the desired level of interaction, while also considering important physicochemical properties that impact the compound's stability, solubility, and cell permeability.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$30.00
$52.00
$122.00
$367.00
25
(3)

Disrupts the Golgi apparatus and vesicular transport. Given Jaw1's involvement in vesicle transport, this compound can indirectly affect its function.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$152.00
$515.00
(1)

Ionophore that disrupts vesicular transport and endosomal processes, potentially impacting Jaw1-associated pathways.

Nocodazole

31430-18-9sc-3518B
sc-3518
sc-3518C
sc-3518A
5 mg
10 mg
25 mg
50 mg
$58.00
$83.00
$140.00
$242.00
38
(2)

Microtubule-disrupting agent that can affect intracellular transport, potentially influencing processes where Jaw1/LRMP plays a role.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

PI3K inhibitor. Given the broad roles of PI3K in various cellular processes, it can modulate pathways associated with Jaw1.

Dynamin Inhibitor I, Dynasore

304448-55-3sc-202592
10 mg
$87.00
44
(2)

Inhibitor of dynamin, which is involved in vesicle formation, and can thus potentially affect Jaw1-related processes.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Another PI3K inhibitor, impacting various intracellular processes, which might indirectly influence the functions associated with Jaw1.

Manumycin A

52665-74-4sc-200857
sc-200857A
1 mg
5 mg
$215.00
$622.00
5
(1)

Ras farnesyl transferase inhibitor which can impact signal transduction pathways, potentially intersecting with processes that Jaw1 is involved in.

Tunicamycin

11089-65-9sc-3506A
sc-3506
5 mg
10 mg
$169.00
$299.00
66
(3)

Inhibits N-linked glycosylation in the ER, affecting protein transport and potentially impacting pathways in which Jaw1/LRMP operates.

eIF4E/eIF4G Interaction Inhibitor, 4EGI-1

315706-13-9sc-202597
10 mg
$260.00
14
(1)

ER-associated degradation (ERAD) inhibitor that affects protein transport and folding, potentially influencing processes related to Jaw1/LRMP.

Pitstop 2

1419093-54-1sc-507418
10 mg
$360.00
(0)

Clathrin inhibitor, affecting clathrin-mediated endocytosis and potentially disrupting processes where Jaw1 plays a role.